The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Convalescent plasma therapy for B-cell–depleted patients with protracted COVID-19
Open accessAbstract
Anti-CD20 monoclonal antibodies are widely used for the treatment of hematological malignancies or autoimmune disease but may be responsible for a secondary humoral deficiency. In the context of COVID-19 infection, this may prevent the elicitation of a specific SARS-CoV-2 antibody response. We report a series of 17 consecutive patients with profound B-cell lymphopenia and prolonged COVID-19 symptoms, negative immunoglobulin G (IgG)-IgM SARS-CoV-2 serology, and positive RNAemia measured by digital polymerase chain reaction who were treated with 4 units of COVID-19 convalescent plasma. Within 48 hours of transfusion, all but 1 patient experienced an improvement of clinical symptoms. The inflammatory syndrome abated within a week. Only 1 patient who needed mechanical ventilation for severe COVID-19 disease died of bacterial pneumonia. SARS-CoV-2 RNAemia decreased to below the sensitivity threshold in all 9 evaluated patients. In 3 patients, virus-specific T-cell responses were analyzed using T-cell enzyme-linked immunospot assay before convalescent plasma transfusion. All showed a maintained SARS-CoV-2 T-cell response and poor cross-response to other coronaviruses. No adverse event was reported. Convalescent plasma with anti–SARS-CoV-2 antibodies appears to be a very promising approach in the context of protracted COVID-19 symptoms in patients unable to mount a specific humoral response to SARS-CoV-2.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Grifoni, A., Weiskopf, D., Ramirez, S. I., Mateus, J., Dan, J. M., Moderbacher, C. R., Rawlings, S. A., Sutherland, A., Premkumar, L., Jadi, R. S., et al. (2020) · Cell · doi:10.1016/j.cell.2020.05.015 · Cited by 3,595
Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients
Hadjadj, J., Yatim, N., Barnabei, L., Corneau, A., Boussier, J., Smith, N., Péré, H., Charbit, B., Bondet, V., Chenevier-Gobeaux, C., et al. (2020) · Science · doi:10.1126/science.abc6027 · Cited by 2,984 · cited 6×
“Time from COVID-19 symptoms onset to CPT, median (range), d 56 (7-83)”
InfluentialSelf-citationAntibody Responses to SARS-CoV-2 in Patients With Novel Coronavirus Disease 2019
Zhao, J., Yuan, Q., Wang, H., Liu, W., Liao, X., Su, Y., Wang, X., Yuan, J., Li, T., Li, J., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa344 · Cited by 2,607
B-cell depletion with rituximab in relapsing-remitting multiple sclerosis
Hauser, S. L., Waubant, E., Arnold, D. L., Vollmer, T., Antel, J., Fox, R. J., Bar-Or, A., Panzara, M., Sarkar, N., Agarwal, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0706383 · Cited by 2,439
Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma
Shen, C., Wang, Z., Zhao, F., Yang, Y., Li, J., Yuan, J., Wang, F., Li, D., Yang, M., Xing, L., et al. (2020) · JAMA · doi:10.1001/jama.2020.4783 · Cited by 2,277
A minimal common outcome measure set for COVID-19 clinical research
Marshall, J. C., Murthy, S., Diaz, J., Adhikari, N. K., Angus, D. C., Arabi, Y. M., Baillie, K., Bauer, M., Berry, S., Blackwood, B., et al. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30483-7 · Cited by 1,641
Li, L., Zhang, W., Hu, Y., Tong, X., Zheng, S., Yang, J., Kong, Y., Ren, L., Wei, Q., Mei, H., et al. (2020) · JAMA · doi:10.1001/jama.2020.10044 · Cited by 1,206
Mair-Jenkins, J., Saavedra-Campos, M., Baillie, J. K., Cleary, P., Khaw, F.-M., Lim, W. S., Makki, S., Rooney, K. D., Convalescent Plasma Study Group, Nguyen-Van-Tam, J. S., et al. (2015) · Journal of Infectious Diseases · doi:10.1093/infdis/jiu396 · Cited by 983
Hawker, K., O'Connor, P., Freedman, M. S., Calabresi, P. A., Antel, J., Simon, J., Hauser, S., Waubant, E., Vollmer, T., Panitch, H., et al. (2009) · Annals of Neurology · doi:10.1002/ana.21867 · Cited by 934
Determinants of COVID-19 disease severity in patients with cancer
Robilotti, E. V., Babady, N. E., Mead, P. A., Rolling, T., Perez-Johnston, R., Bernardes, M., Bogler, Y., Caldararo, M., Figueroa, C. J., Glickman, M. S., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0979-0 · Cited by 628
Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience
Salles, G., Barrett, M., Foà, R., Maurer, J., O’Brien, S., Valente, N., Wenger, M., & Maloney, D. G. (2017) · Advances in Therapy · doi:10.1007/s12325-017-0612-x · Cited by 620
ddPCR: a more accurate tool for SARS-CoV-2 detection in low viral load specimens
Suo, T., Liu, X., Feng, J., Guo, M., Hu, W., Guo, D., Ullah, H., Yang, Y., Zhang, Q., Wang, X., et al. (2020) · Emerging Microbes & Infections · doi:10.1080/22221751.2020.1772678 · Cited by 450
Zeng, Q.-L., Yu, Z.-J., Gou, J.-J., Li, G.-M., Ma, S.-H., Zhang, G.-F., Xu, J.-H., Lin, W.-B., Cui, G.-L., Zhang, M.-M., et al. (2020) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiaa228 · Cited by 330
Woyach, J. A., Smucker, K., Smith, L. L., Lozanski, A., Zhong, Y., Ruppert, A. S., Lucas, D., Williams, K., Zhao, W., Rassenti, L., et al. (2014) · Blood · doi:10.1182/blood-2013-09-527853 · Cited by 280 · cited 1×
“22 Interestingly, the rapid clinical improvement observed after CPT correlated strongly with virological clearance, as demonstrated by the decrease of SARS-CoV-2 RNAemia using an innovative ddPCR technology that allows precise quanti fi cation of SARS-CoV-2 RNAemia.”
Collecting and evaluating convalescent plasma for COVID‐19 treatment: why and how?
Tiberghien, P., de Lamballerie, X. N., Morel, P., Gallian, P., Lacombe, K., & Yazdanpanah, Y. (2020) · Vox Sanguinis · doi:10.1111/vox.12926 · Cited by 168
Self-citationTepasse, P., Hafezi, W., Lutz, M., Kühn, J., Wilms, C., Wiewrodt, R. G., Sackarnd, J., Keller, M., Schmidt, H., & Vollenberg, R. (2020) · British Journal of Haematology · doi:10.1111/bjh.16896 · Cited by 146
Lower prevalence of antibodies neutralizing SARS-CoV-2 in group O French blood donors
Gallian, P., Pastorino, B. A. M., Morel, P., Chiaroni, J., Ninove, L., & de Lamballerie, X. N. (2020) · Antiviral Research · doi:10.1016/j.antiviral.2020.104880 · Cited by 138
Self-citationDetecting biomarkers with microdroplet technology
Taly, V., Pekin, D., Abed, A. I. E., & Laurent‐Puig, P. (2012) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2012.05.001 · Cited by 125
Humoral and Cellular Immune Responses after Influenza Vaccination in Kidney Transplant Recipients
Candon, S., Thervet, É., Lebon, P., Suberbielle, C., Zuber, J., Lima, C., Charron, D. J., Legendre, C., & Chatenoud, L. (2009) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2009.02787.x · Cited by 122
Self-citationConsequences of B-Cell-Depleting Therapy: Hypogammaglobulinemia and Impaired B-Cell Reconstitution
Sacco, K. A., & Abraham, R. S. (2018) · Immunotherapy · doi:10.2217/imt-2017-0178 · Cited by 120
COVID-19–Related Collapsing Glomerulopathy in a Kidney Transplant Recipient
Lazareth, H., Péré, H., Binois, Y., Chabannes, M., Schurder, J., Bruneau, T., Karras, A., Thervet, É., Rabant, M., Veyer, D. L., et al. (2020) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2020.06.009 · Cited by 52
Self-citationPerotti, C. G., Fante, C. D., Baldanti, F., Franchini, M., Percivalle, E., Nepita, E. V., Seminari, E. M., SILVESTRI, A. D., Bruno, R., & Klersy, C. (2020) · Internal and Emergency Medicine · doi:10.1007/s11739-020-02384-2 · Cited by 40
Cited by
Viral targets for vaccines against COVID-19
Dai, L., & Gao, G. F. (2021) · Nature Reviews Immunology · doi:10.1038/s41577-020-00480-0 · Cited by 1,048
Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia
Herishanu, Y., Avivi, I., Aharon, A., Shefer, G., Levi, S., Bronstein, Y., Morales, M., Ziv, T., Shorer Arbel, Y., Scarfò, L., et al. (2021) · Blood · doi:10.1182/blood.2021011568 · Cited by 614
Metadata
- Authors
- Hueso, T., Pouderoux, C., Péré, H., Beaumont, A.-L., Raillon, L.-A., Ader, F., Chatenoud, L., Eshagh, D., Szwebel, T.-A., Martinot, M., Camou, F., Crickx, E., Michel, M., Mahevas, M., Boutboul, D., Azoulay, E., Joseph, A., Hermine, O., Rouzaud, C., Faguer, S., Petua, P., Pommeret, F., Clerc, S., Planquette, B., Merabet, F., London, J., Zeller, V., Ghez, D., Veyer, D., Ouedrani, A., Gallian, P., Pacanowski, J., Mékinian, A., Garnier, M., Pirenne, F., Tiberghien, P., & Lacombe, K.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2020-11-12
- Volume
- 136
- Issue
- 20
- Pages
- 2290-2295
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W3087063072
- Cited by
- 281
- References
- 22
- FWCI
- 7.42
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.